Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (9757)	6/17/1998 12:51:00 PM
From: VLAD	Respond to of 23519

I suggest that anyone wanting to do something e-mail Astra for support. There is heavy short money trying to crush us and help from a big player can only help. Astra trades on the NYSE It is to their own interest to give MUSE the proper perspective as to its place in ED versus Viagra. Astra has said in Sweden that they are shooting for $100,000,000.00 in MUSE sales in 1998. Janssen should also have a sales goal that can be published. One final fact regarding the class action lawsuit. It may never get to court (Vivus is hoping to see it thrown out ASAP). If it did go to court it would take over a year to go to trial.

To: VLAD who wrote (9757)	6/17/1998 12:54:00 PM
From: blankmind	Read Replies (1) \| Respond to of 23519

- VLAD - thanks for the infor - And I can assure everyone else that VLAD's posts & talks with mangement are about 100% accurate.

To: VLAD who wrote (9757)	6/17/1998 1:19:00 PM
From: Frostman	Read Replies (1) \| Respond to of 23519

Vlad, nice Job! 2)Vivus is fully aware of the shareholder sentiment and has no control of the stock price including the effects of the shorters. NASDaq stock prices appear to be largely the result of perception, an item that can be controlled to a degree with effective PR. 3)The main focus now is on production (new plant) and marketing. vivus again has no control of external factors ie media hype of Viagra. Perception of Vivus is the result of factors like external media hype, an element that can be countered to a degree with effective PR. 5)Vivus looking very closely at costs and if it finds that the new sales reps are not effective they will seriously consider getting a large player to market/sell MUSE. That is new and good news! 6)Vivus has discussed PR help from Astra. Astra is very conservative in advertising and may help out but no promises. This is new and good news! 7)Vivus knows that things look ugly in terms of perception, stock price, Viagra--they are still confident that things will turn around in Q3 and Q4. They feel that US script numbers are the main focus and not international sales. * I believe the entire picture should be the main focus IMHO. PS, I have been buying lately. How's that for PR? The stock just went under six, and another friend gets a margin call. Jump in ASTRA, or VIVUS, a kind word will help. I have little doubt that the future of Vivus is a good investment, but the carnage along the way upsets me folks, sorry. Frostman